Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Cash from Financing Activities (2016 - 2025)

Abeona Therapeutics has reported Cash from Financing Activities over the past 14 years, most recently at $3.6 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $3.6 million for Q4 2025, down 31.99% from a year ago — trailing twelve months through Dec 2025 was $26.0 million (down 74.99% YoY), and the annual figure for FY2025 was $26.0 million, down 74.99%.
  • Cash from Financing Activities for Q4 2025 was $3.6 million at Abeona Therapeutics, down from $5.2 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for ABEO hit a ceiling of $73.7 million in Q2 2024 and a floor of -$299000.0 in Q3 2024.
  • Median Cash from Financing Activities over the past 5 years was $6.2 million (2021), compared with a mean of $13.3 million.
  • Peak annual rise in Cash from Financing Activities hit 636100.0% in 2024, while the deepest fall reached 101.3% in 2024.
  • Abeona Therapeutics' Cash from Financing Activities stood at $16.3 million in 2021, then surged by 161.87% to $42.8 million in 2022, then plummeted by 82.54% to $7.5 million in 2023, then decreased by 28.83% to $5.3 million in 2024, then plummeted by 31.99% to $3.6 million in 2025.
  • The last three reported values for Cash from Financing Activities were $3.6 million (Q4 2025), $5.2 million (Q3 2025), and $10.5 million (Q2 2025) per Business Quant data.